Premium
Preparation and characterization of new challenge stocks of SIVmac32H J5 following rapid serial passage of virus in vivo
Author(s) -
Ferguson D.,
WadeEvans A.,
Elsley W.,
Sangster R.,
Silvera P.,
MacManus S.,
Davis G.,
Corcoran T.,
Berry N.,
Brown S.,
Jenkins A.,
Cowie J.,
Sethi M.,
Hull R.,
Stebbings R.,
Lines J.,
Norley S.,
Stott E.J.,
Almond N.
Publication year - 2007
Publication title -
journal of medical primatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.31
H-Index - 42
eISSN - 1600-0684
pISSN - 0047-2565
DOI - 10.1111/j.1600-0684.2007.00224.x
Subject(s) - biology , in vivo , virus , virology , ex vivo , simian immunodeficiency virus , lymphatic system , spleen , serial passage , pathology , immunology , medicine , genetics
Background A new challenge stock of the simian immunodeficiency virus SIVmacJ5 has been produced following passage in vivo . Methods SIVmacJ5 3/92 (J5M), was passaged serially through cynomolgus macaques ( Macaca fascicularis ) by intravenous inoculation of infected spleen cells isolated and prepared 14 days post‐infection. Two challenge stocks, SIVmacJ5 S61MLN and SIVmacJ5 S62spl, were prepared by culture of lymphoid tissue ex vivo . Results These virus stocks appeared better adapted for replication in M. fascicularis as demonstrated by a greater persistence of recoverable live virus from the periphery and increased pathology in lymphoid tissues 20 weeks post‐challenge as detected by immunohistochemistry. Sequence analysis of the envelope gene from these stocks did not identify marked diversification of sequence as a result of this procedure. Conclusions These stocks display more robust peripheral persistence and tissue pathology in cynomolgus macaques and should prove valuable analysing recombinant vaccines based upon SIVmacJ5 transgenes.